Abstract
The tumor suppressor protein p53 mediates critical cellular functions including regulation of cell cycle, apoptosis, DNA repair, and senescence. This protein has been found to be inactivated or functionally down-regulated in several malignancies such as Li- Fraumeni syndrom, hepatocellular carcinoma, breast cancer, cervical cancer, and acute myeloid leukemia. Thus, p53 represents an attractive target for therapeutic design and development of new anticancer agents. The most clinically used cytotoxic agents target stabilization of wt-p53 through DNA damage and are associated with several unwanted and life threatening side effects. There are a number of recently developed approaches that hold promise for non-genotoxic reactivation of p53. Earlier, we have reported various inhibitors of p53 and their importance to prevent unwanted death of normal cells in a variety of diseases [1]. To extend p53 protein as new target for anticancer agents, in this review we discussed the mechanisms of p53 inactivation. Subsequently, we described some of recently developed non-genotoxic activators of p53 and their significance in various neoplastic disorders. Additionally, we summarized advantages of nongenotoxic p53-activating agents over conventional anticancer therapy and challenges in future of p53 based therapy.
Keywords: Apoptosis, Non-genotoxic, p53-inactivation, p53-activation, Mdm2, tumor suppressor protein, DNA repair, senescence, Fraumeni syndrom, hepatocellular carcinoma, cytotoxic agents
Current Medicinal Chemistry
Title: Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Volume: 18 Issue: 7
Author(s): S. K. Nayak, P. S. Panesar and H. Kumar
Affiliation:
Keywords: Apoptosis, Non-genotoxic, p53-inactivation, p53-activation, Mdm2, tumor suppressor protein, DNA repair, senescence, Fraumeni syndrom, hepatocellular carcinoma, cytotoxic agents
Abstract: The tumor suppressor protein p53 mediates critical cellular functions including regulation of cell cycle, apoptosis, DNA repair, and senescence. This protein has been found to be inactivated or functionally down-regulated in several malignancies such as Li- Fraumeni syndrom, hepatocellular carcinoma, breast cancer, cervical cancer, and acute myeloid leukemia. Thus, p53 represents an attractive target for therapeutic design and development of new anticancer agents. The most clinically used cytotoxic agents target stabilization of wt-p53 through DNA damage and are associated with several unwanted and life threatening side effects. There are a number of recently developed approaches that hold promise for non-genotoxic reactivation of p53. Earlier, we have reported various inhibitors of p53 and their importance to prevent unwanted death of normal cells in a variety of diseases [1]. To extend p53 protein as new target for anticancer agents, in this review we discussed the mechanisms of p53 inactivation. Subsequently, we described some of recently developed non-genotoxic activators of p53 and their significance in various neoplastic disorders. Additionally, we summarized advantages of nongenotoxic p53-activating agents over conventional anticancer therapy and challenges in future of p53 based therapy.
Export Options
About this article
Cite this article as:
K. Nayak S., S. Panesar P. and Kumar H., Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future, Current Medicinal Chemistry 2011; 18 (7) . https://dx.doi.org/10.2174/092986711794940833
DOI https://dx.doi.org/10.2174/092986711794940833 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Calcium Carbonate Microparticles as Carriers of <sup>224</sup>Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Current Radiopharmaceuticals Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry Transdermal Delivery of 5-Fluorouracil for Induced Ehrlich Ascites Carcinoma Tumor in Balb/c Mice and Pharmacokinetic Study
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on Stimuli Responsive Hydrogel Drug Delivery System
Recent Patents on Drug Delivery & Formulation Activity of Saponins from Medicago species Against HeLa and MCF-7 Cell Lines and their Capacity to Potentiate Cisplatin Effect
Anti-Cancer Agents in Medicinal Chemistry Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry Epithelial Organotypic Cultures: A Viable Model to Address Mechanisms of Carcinogenesis by Epitheliotropic Viruses
Current Topics in Medicinal Chemistry Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets An Overview on the Development of New Potentially Active Camptothecin Analogs Against Cancer
Mini-Reviews in Medicinal Chemistry NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design